Good evening :)
Switch to
Place Order

Laurus Labs Ltd

LAURUSLABS
Health CarePharmaceuticals
MidcapWith a market cap of ₹27,441 cr, stock is ranked 175
Moderate RiskStock is 2.44x as volatile as Nifty
511.405.40 (-1.04%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
MidcapWith a market cap of ₹27,441 cr, stock is ranked 175
Moderate RiskStock is 2.44x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
27.90
PB RatioPB Ratio
10.55
Dividend YieldDiv. Yield
0.39%
Sector PESector PE
38.07
Sector PBSector PB
5.10
Sector Div YldSctr Div Yld
0.67%

Forecast & RatingsDetailed Forecast 

50%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Laurus Labs Private Ltd is a research and development pharmaceutical company which manufactures active pharmaceutical ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Investor PresentationView older 

Oct 28, 2021

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Financial TrendFinancial statements 

20182019202020212.092.312.844.840.170.090.260.98
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Related Party Transactions 
Announced OnNov 19, 2021

Laurus Labs Limited has informed the Exchange about related Party Transactions | Download

Laurus Labs Limited has informed the Exchange about related Party Transactions | Download

Press Release 
Announced OnNov 19, 2021

Laurus Labs Limited has informed the Exchange regarding a press release dated November 19, 2021, titled "Laurus Labs acquires substantial minority stake in a CAR-Tcell therapy company - ImmunoACT.". | Download

Laurus Labs Limited has informed the Exchange regarding a press release dated November 19, 2021, titled "Laurus Labs acquires substantial minority stake in a CAR-Tcell therapy company - ImmunoACT.". | Download

Cash Dividend 
Ex. DateNov 17, 2021

Interim • Div/Share: ₹ 0.8

See all events